Silver Book Fact

Treatment with bisphosphonates are highly cost-effective in women over the age of 70 with osteoporosis and a previous fracture.

Fleurence R, Iglesias C, Johnson J. The Cost Effectiveness of Bisphosphonates for the Prevention and Treatment of Osteoporosis: A structured review of the literature. PharmacoEcon. 2007; 25(11): 913-33. http://www.ncbi.nlm.nih.gov/pubmed/17960951

Reference

Title
The Cost Effectiveness of Bisphosphonates for the Prevention and Treatment of Osteoporosis: A structured review of the literature
Publication
PharmacoEcon
Publication Date
2007
Authors
Fleurence R, Iglesias C, Johnson J
Volume & Issue
Volume 25, Issue 11
Pages
913-33
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Economic Value

Related Facts

  • The Study of Osteoporotic Fractures, which began over 20 years ago, found that bone mineral density (BMD) of the hip is one of the best predictors of fracture for women,…  
  • Risedronate, a bisphosphonate, has been shown to increase vertebral bone mineral density (BMD) by around 5% and hip BMD by 2% to 3% in postmenopausal women with osteoporosis.  
  • Raloxifene, a selective estrogen receptor modulator (SERM) has been shown to increase vertebral bone mineral density (BMD) by 2% to 3% after 3 years.  
  • Teriparatide, or human recombinant PTH, has been shown to decrease vertebral fractures by 65% to 69%, and non-vertebral fragility fractures by around 53%.  
  • A study of a number of osteoporosis treatments found cost-effectiveness ratios as low as $55,000 per QALY.